PDX INSIGHTS
PIONEERING CANCER RESEARCH
Model Details

Patient Information for Model: HCI-015

Model Contact
Model: HCI-015
Model Contact: Alana Welm
Institution: HCI Breast PDX Program
Email: Alana.Welm@hci.utah.edu

Patient Information
Clinical Timeline

Color Keys:
 
 Positive
 
 Negative
 
 N/A

Clinical Information at Collection
Clinical Biomarkers/Mutations at Collection
Pathology Information at Collection

Model Information for Model: HCI-015

Model Details - Initial Implantation of Patient Tissue
Biomarkers & Mutations
Model Details - Acceptable Conditions for Passaging
Mutations (Cancer Gene Census List)
Mutation data is currently not available.

CNV
There are no omics data for this model.


Drug Studies for Model: HCI-015

Treatment Response Across All Studies
CR <=-95% to -100% PR <-30% to >-95% SD >=-30% to +20% PD >=+20% NA
Study Metadata
Study Design
Treatment Results





Histology Information for Model: HCI-015
There are no histology images for this model.













Metastasis Information for Model: HCI-015
 
Patient
PDX
Abdomen
Adrenal gland
Bone
Bone (de novo)
Bones
Brain
CTC
Chest
Chest wall
Contralateral Breast
Dura
Fallopian Tubes
Head
Kidney
LMD
Liver
Lung
Lymph node
Lymph nodes
Neck
None
Ovary
Pancreas
Pericardium
Peritoneal cavity
Peritoneum
Pleura
Pleural effusion
Shoulder
Skin
Spine
Spleen
Thoracic Spine
Thymus
medistinal and right hilar

Patient Treatment Information for Model: HCI-015

Event IdTreatmentTreatment SettingAge at StartAge at EndDurationClinical Response
10Doxorubicon, Cyclophosphamide/Paclitaxel Neoadjuvant48.3348.67124 daysProgressive disease
20Radiation Therapy Brain Adjuvant49.0849.1629 daysProgressive disease
25Radiation Therapy Brain Adjuvant49.2549.3329 daysProgressive disease













Please wait...